All News

RheumNow Podcast square

Mono- and Oligo- are Different (8.18.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.

Read Article
biosimilars,light,bulbs,different

The Adalimumab Biosimilar Glut

d Jack Cush, MD

In 2023, three marketed biosimilars (Actemra, Stelara, Humira) had their patents expire, opening opportunities for multiple new biosimilars; but with competition comes a word salad of new drug names, confusion and nonsensical discounts.

Read Article
RheumNow Podcast square

Pizza and Rheumatoid Arthritis (8.11.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Read Article
Chinese study of 5530 RA pts found 546 (9.9%) who developed diabetes. DM risk was significantly lower w/ bDMARD (HR 0.51), MTX (HR 0.50) and HCQ (HR 0.52). TNF inhibitors were also protective (HR 0.69). https://t.co/hdkyqFXbbu https://t.co/baQORpq1HP

Links:

Dr. John Cush RheumNow ( View Tweet)
HEALTH DISPARITIES: Lancet study shows from 2000-2019, all-cause mortality was signif. higher in the American Indian/Alaska Native (1028/100K) & Blacks (953·/100K) compared to Whites (802); but lower in Asians (442) & Latinos (595) https://t.co/g8Z3h6BYw8 https://t.co/Ckz1L3O0W7

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums: Have a rheumatology question or case for Dr. Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/uY9Mwyrsn3

Links:

Dr. John Cush RheumNow ( View Tweet)

DSB.pill2__0.jpg

WHO Safety Study of Five TNF Inhibitors

d Jack Cush, MD

Large scale analysis of adverse events (AEs) in World Health Organization (WHO) VigiAccess database showed no new safety signals associated with long-standing use of five TNFα inhibitors. 

Read Article
Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/vGt12ul6iy https://t.co/044BScmSYc

Links:

Dr. John Cush RheumNow ( View Tweet)
BE OPTIMAL study: Bimekizumab vs adalumumab in 702 #PsA pts, showed sustained 52 week ACR50 responses at wk 52: 54% BKZ v 50% ADA; PASI 100 61% BKZ v 48% ADA. Serious AE seen in 6.6% of BKZ patients, 1 death and 7.7% w/ Candida (vs 0.7% w/ ADA) https://t.co/4g3j5OoKyy https://t.co/g4SQubSCXg

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Anti-Drug Antibodies with Biologics (7.14.2023)

d Jack Cush, MD

Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!

Read Article
antibody (Keep)

Antidrug Antibodies Impair Response to Biologic Drugs

d Jack Cush, MD

Monitoring for antidrug antibodies with biologic has not been routine in rheumatology but a new study suggests that antidrug antibodies correlate with nonresponse to bDMARDs in rheumatoid arthritis (RA) patients.

Read Article
Metanalysis 62 RCTs & 16 LTE RCTs looks at neoplasia risk in JAKi, TNFi, MTX, PBO. Total CA rate=1.15/100PYs in RCTs. No diff in all CA between JAKi vs PBO or JAKi vs MTX (IRR 0.77); but JAKi had more CA than TNFi (1.50; 1.16, 1.94) https://t.co/aiJHQ5oPqt https://t.co/8MjJv728sh

Links:

Dr. John Cush RheumNow ( View Tweet)
Covid lung pneumonia corona (keep)

RA Biologics Lower COVID-19 Deaths, but Not Recovery Time

d Jack Cush, MD

Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?

Read Article
In Memoriam: Dr. K. Frank Austen (1928-2023) Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95. https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @AurelieRheumo : The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8) Use of TNFi & orthopedic implants associated w/ OAI risk Mortality however similar in RA and non RA groups #EULAR23 POS0033

Dr. John Cush RheumNow ( View Tweet)

computer screen safety

ICYMI: Drug Safety Differences with New Novel Therapies in RA

d Jack Cush, MD

Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.

Read Article
Achilles,ankle,heel

ICYMI: GRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis

d Jack Cush, MD

GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes. 

Read Article
Paradoxical PsO (PP) studied in 2867 RA & 5316 SpA pts. 136 (1.7%) had paradox. Rxn, median 12 mos post TNFi [pustular (60%) or palmoplantar (31%)]. 73% PP favorably switched to other TNFi 46% or non-TNFi 27%. RA PP took SSZ, HCQ, LEF; SpA PP more smokers https://t.co/w1EQEvHbeG https://t.co/aAwKxdNYk1

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Scleroderma – Thick and Thin (6.30.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week from RheumNow.com. This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.

Read Article
Paradoxical Psoriasis in Kids Taking TNF Inhibitors A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor. https://t.co/f1KmICaGNF https://t.co/N0jxIJbv7Q

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.